A detailed history of Handelsbanken Fonder Ab transactions in Harmony Biosciences Holdings, Inc. stock. As of the latest transaction made, Handelsbanken Fonder Ab holds 11,300 shares of HRMY stock, worth $389,850. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,300
Previous 9,800 15.31%
Holding current value
$389,850
Previous $296,000 52.7%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 04, 2024

BUY
$30.0 - $39.95 $45,000 - $59,925
1,500 Added 15.31%
11,300 $452,000
Q2 2024

Aug 05, 2024

BUY
$28.81 - $33.01 $48,977 - $56,117
1,700 Added 20.99%
9,800 $296,000
Q1 2023

Apr 28, 2023

SELL
$30.8 - $53.92 $3.7 Million - $6.47 Million
-120,000 Reduced 93.68%
8,100 $264,000
Q4 2022

Feb 07, 2023

BUY
$45.4 - $60.91 $5.45 Million - $7.31 Million
120,000 Added 1481.48%
128,100 $7.06 Million
Q4 2021

Feb 08, 2022

BUY
$34.09 - $43.91 $276,129 - $355,671
8,100 New
8,100 $345,000

Others Institutions Holding HRMY

About Harmony Biosciences Holdings, Inc.


  • Ticker HRMY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,161,400
  • Market Cap $2.04B
  • Description
  • Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...
More about HRMY
Track This Portfolio

Track Handelsbanken Fonder Ab Portfolio

Follow Handelsbanken Fonder Ab and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Handelsbanken Fonder Ab, based on Form 13F filings with the SEC.

News

Stay updated on Handelsbanken Fonder Ab with notifications on news.